TOP > 外国特許検索 > NOVEL FLUORINE-CONTAINING BISPHOSPHONIC ACID DERIVATIVE AND USE THEREOF

NOVEL FLUORINE-CONTAINING BISPHOSPHONIC ACID DERIVATIVE AND USE THEREOF

外国特許コード F160008854
整理番号 (S2015-0409-N0)
掲載日 2016年9月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP052960
国際公開番号 WO 2016125757
国際出願日 平成28年2月1日(2016.2.1)
国際公開日 平成28年8月11日(2016.8.11)
優先権データ
  • 特願2015-018260 (2015.2.2) JP
発明の名称 (英語) NOVEL FLUORINE-CONTAINING BISPHOSPHONIC ACID DERIVATIVE AND USE THEREOF
発明の概要(英語) In the present invention, a series of fluorine-containing bisphosphonic acids where alkylamine side chains have been added to the carbon atoms of P-C(F)-P, a series of fluorine-containing bisphosphonic acids where heterocyclic groups containing amino groups or nitrogen groups substituted for heterocyclic groups have been added, and a series of fluorine-containing bisphosphonic acid derivatives where the acid moiety thereof has been esterified by alkoxymethyl groups such as POM groups, n-butanoyloxymethyl (BuOM) groups, and the like, that is, fluorine-containing bisphosphonic acids and fluorine-containing bisphosphonic acid derivatives represented by general formula (I) (where each symbol is as defined in the specification), are capable of efficiently inducing propagation of peripheral blood γδ-type T cells that express Vγ2Vδ2-type T cell receptors which have superior cytotoxicity against tumor cells and viral infection cells, and sensitizing tumor cells and viral infection cells to the cytotoxicity of γδ-type T cells.
特許請求の範囲(英語) [claim1]
1. Below-mentioned general formula (i):
(In formula, Cy to be the phenyl group or complex ring basis, Y the hydrogen atom, the alkyl group and the halogen atom, the halogenation alkyl group, hydroxyl group, the halogen atom or the aryl basis which is possible to be substituted with alkoxy group, or, to be the aralkyl oxy basis, F to be the fluorine atom, P to display the phosphorus atom, R to be the hydrogen atom or the alkyl group, R [1] and R [2], differing identically or mutually, to be the hydrogen atom or the alkyl carbonyl oxy alkyl group, j to display the quantity of 0 or 1, as for m displaying the quantity of 0 or 1,n displays the integer of the 1-6. However, Cy 3 - is the [pirijiru] basis, m is 1, n is 1, Y is the hydrogen atom, R [1] and R [the case where 2] is the hydrogen atom is excluded) with the chemical compound which is displayed or the salt which that pharmacy is allowed.
[claim2]
2. In general formula (i), Cy is phenyl group, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim3]
3. In general formula (i), the 1-3 where Cy is chosen from the nitrogen atom, the sulfur atom and the oxygen atom it is the complex ring basis of the 5-10 member ring to which includes the atom, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim4]
4. In general formula (i), it is the complex ring basis of 5 or 6 member rings which include 1 or 2 atoms where Cy is chosen from the nitrogen atom and the sulfur atom, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim5]
5. In general formula (i), Cy the [imidazoriru] basis, the [chiazoriru] basis, the [pirijiru] basis and the [pirimijiru] basis, or 7 - is the [azaindoriru] basis, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim6]
6. In general formula (i), Y the hydrogen atom, C [1-3] alkyl group, the halogen atom, is the halogenation alkyl group or phenyl group, R [1] and R [2] differs identically or mutually, it is the hydrogen atom or C [2-7] alkyl carbonyl oxy - C [1-3] alkyl group, either of the claim 1-5 in 1 sections the chemical compound of statement or that the salt which is allowed pharmacy.
[claim7]
7. In general formula (i), j is 1, Cy is the [imidazoriru] basis, Y is the hydrogen atom or the halogen atom, R [1] and R [2] differs identically or mutually, it is the hydrogen atom or C [2-7] alkyl carbonyl oxy - C [1-3] alkyl group, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim8]
8. In general formula (i), j is 0, Y is the hydrogen atom or C [1-3] alkyl group, R [1] and R [2] differs identically or mutually, it is the hydrogen atom or C [2-7] alkyl carbonyl oxy - C [1-3] alkyl group, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim9]
9. In general formula (i), j is 0, Y is the hydrogen atom, R is the hydrogen atom, R [1] and R [2] is the hydrogen atom, in claim 1 the chemical compound of statement or that the salt which is allowed pharmacy.
[claim10]
10. In general formula (i), j is 0, Y is C [1-3] alkyl group, R is C [1-6] alkyl group, R [1] and R [2] is the hydrogen atom, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim11]
11. In general formula (i), j is 1, Cy is the [imidazoriru] basis, Y is the hydrogen atom, R [1] and R [2] differs identically or mutually, hydrogen atom or [pibaroiruokishimechiru] (POM) it is the basis, the chemical compound of claim 1 statement or that the salt which is allowed pharmacy.
[claim12]
12. Either of the chemical compound which is displayed with the below-mentioned formula one or that the salt which is allowed pharmacy:
[claim13]
13. In either of the claim 1-12 in 1 sections the chemical compound of statement or that the medicine composition which includes the salt which is allowed pharmacy as the active ingredient.
[claim14]
14. It is the anti- tumor cell medicine, in claim 13 the medicine composition of statement.
[claim15]
15. It is the anti- virus infection cell medicine, in claim 13 the medicine composition of statement.
[claim16]
16. It is the lymphocyte treatment agent, in claim 13 the medicine composition of statement.
[claim17]
17. Either of the claim 1-12 in 1 sections the chemical compound of statement or processing method of the lymphocyte in internal it features that the effective quantity of the salt which that pharmacy is allowed is prescribed to the organism.
[claim18]
18. Either of the claim 1-12 in 1 sections the chemical compound of statement or that multiplication of the .gamma..delta. type T cell which features that the effective quantity of the salt which is allowed pharmacy is prescribed to the organism and/or induction method.
[claim19]
19. Either of the claim 1-12 in 1 sections the chemical compound of statement or that multiplication control method of the tumor cell and the virus infection cell which feature that the effective quantity of the salt which is allowed pharmacy is prescribed to the organism.
[claim20]
20. Either of the claim 1-12 in 1 sections the chemical compound of statement or that remedy method of the cancer and the virus infection symptom which feature that the effective quantity of the salt which is allowed pharmacy is prescribed to the organism.
[claim21]
21. Multiplication of the .gamma..delta. type T cell which features that it operates the inspection body which includes the .gamma..delta. type T cell either of the claim 1-12 the chemical compound of statement or the salt which that pharmacy is allowed, in vitro in 1 sections and/or induction method.
[claim22]
22. Either of the claim 1-12 the chemical compound of statement or by operating the inspection body which includes the .gamma..delta. type T cell which extracted the salt which that pharmacy is allowed, from the organism in 1 sections, the .gamma..delta. type T cell multiplication and/or multiplication control method of the tumor cell and the virus infection cell which include the process which is made to induce, and the process which resets the particular .gamma..delta. type T cell to the organism.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGASAKI UNIVERSITY
  • 発明者(英語)
  • TANAKA YOSHIMASA
  • MIZUTA SATOSHI
  • UEDA HIROSHI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close